Infertility affects roughly one in six adults worldwide, about 17.5% of the population, making it a pervasive global challenge. For decades, assisted reproductive technology (ART), principally in‑vitro fertilization (IVF), has been the primary recourse. Yet conventional IVF remains a labour‑intensive, subjective process: embryologists manually select sperm and grade embryos, and success rates per embryo transfer often stay below 30 % live birth.

Bioengineering is now shifting reproductive medicine from a manual, qualitative craft to an objective, automated, and personalized clinical model. By merging robotics, fluid dynamics, tissue engineering, and genetic tools, scientists are creating solutions that improve gamete selection, embryo culture, uterine receptivity, and genetic safety. The following sections outline how these innovations are reshaping infertility treatment.

Tissue Engineering and Regenerative Approaches

Bioengineering strategies that combine cells, growth factors, and biomaterials are repairing damaged reproductive tissues and restoring organ function.

• Uterine repair – Collagen scaffolds seeded with bone‑marrow mesenchymal stem cells have increased endometrial and muscular cell proliferation, regenerated microvasculature, and improved pregnancy outcomes in rat models to levels comparable with sham‑operated controls. Whole‑uterus transplantation has succeeded in animal studies, though immunogenicity and organ supply remain hurdles for clinical use.
• Ovarian regeneration – Mesenchymal stem cells and bone‑marrow‑derived stem cells have shown promise in regenerating ovarian tissue, improving folliculogenesis, and restoring hormonal balance after chemotherapy‑induced injury. Female germline stem cells (FGSCs) isolated post‑chemoablation can be transplanted to restore long‑term ovarian function and produce offspring without immune rejection. Human amniotic epithelial cells delivered intravenously inhibit granulosa‑cell apoptosis, reduce ovarian inflammation, and raise oocyte numbers in chemoablated mice.
• Organ‑on‑chip models – Patient‑derived vascularised endometrium‑on‑a‑chip (EoC) mimics the dynamic endometrial microenvironment and can predict pregnancy success after IVF‑ET, enabling personalised treatment decisions. Testicular organ‑on‑chips aim to recreate the niche needed for spermatogonial stem‑cell self‑renewal, offering a platform to study spermatogenesis and fertility preservation for prepubertal boys facing gonad‑toxic therapies. Female reproductive organ‑on‑chip systems simulate menstrual‑cycle molecular networks, helping dissect endometrial disorders and optimise embryo‑uterine interactions.

These regenerative and microscale models lay the groundwork for therapies that address structural causes of infertility rather than merely bypassing them.

Microfluidics and IVF‑on‑a‑Chip

Traditional sperm preparation relies on centrifugation, which can induce oxidative stress and DNA fragmentation. Microfluidic devices replace harsh forces with microscopic channels that mimic the natural female tract, allowing only the healthiest, most motile sperm to reach the egg.

• Clinical evidence shows microfluidic sperm selection reduces DNA fragmentation index (DFI) from 6%–18% with centrifugation to near‑zero levels (0.0%–1.9%).
• Because these chips select sperm with superior genomic integrity, fertilization rates increase by over 11% and miscarriage risk declines.
• Microfluidic platforms also enable full IVF‑on‑a‑chip designs that handle fertilization, embryo culture, and selection with high repeatability and biocompatibility .
  

In patients undergoing recurrent IVF, microfluidic chips have yielded significantly higher fertilization rates.

​

AI and Robotics in Embryo Selection

The subjectivity of manual embryo grading is being replaced by artificial intelligence and robotic automation.

• In 2025, the world’s first babies were born from a fully automated, robot‑controlled IVF system developed by Conceivable Life Sciences and tested at Columbia University Fertility Center.
• AI neural networks analyse thousands of time‑lapse embryo images, detecting subtle division patterns invisible to the human eye. In head-to-head tests, AI achieved 81.5% accuracy in predicting clinical pregnancy, whereas human embryologists reached only 51.0%.
• AI‑driven tools such as STAR (Sperm Tracking and Recovery) have rescued previously hopeless cases: in 2025, a system identified 44 viable sperm in a sample from a patient trying to conceive for 18 years, leading to a successful pregnancy.
  

By removing human error and bias, AI‑robotics improve both the efficiency and reliability of ART.

3D Bioprinting of Reproductive Organs

For patients whose infertility stems from organ damage or deficiency, 3D bioprinting offers a way to build functional, living tissue.

• Ovaries – Bioprosthetic ovaries printed from gelatin scaffolds with tailored pore sizes have supported immature egg survival, hormone production, and ovulation in mice. Implanted bioprosthetic ovaries enabled ovulation, natural birth, and lactation.
• Uterus – Thin endometrium (< 7 mm) can cut live‑birth rates by half. Researchers are developing 3D scaffolds loaded with stem cells that provide a physical niche for cellular growth, release growth factors, and stimulate self‑healing of the uterine lining, thereby thickening it and improving implantation odds.

These bioprinted constructs promise to restore native organ physiology for women who have lost ovarian or uterine function due to cancer, genetics, or injury.

Precision Genetics and CRISPR

Genetic tools are preventing inherited disease transmission and correcting infertility‑linked mutations.

• Mitochondrial Replacement Therapy (MRT) – Often called “three‑person IVF", MRT transfers parental nuclear DNA into a donor egg with healthy mitochondria, averting maternal mitochondrial disease while preserving genetic ties to the parents .
• CRISPR‑based gene editing – In 2026, the RMTS‑CRISPR system demonstrated the ability to enter mitochondria and excise mutated DNA, shifting the healthy‑to‑mutated DNA ratio by over 26% in laboratory models. Such approaches could eventually cure mitochondrial disorders within the embryo itself.
• CRISPR also enables correction of nuclear gene mutations that cause infertility (e.g., chromosomal abnormalities or gamete function defects), improving embryo selection and implantation success .
  

These precision genetics techniques expand the preventive power of ART beyond aneuploidy screening to include monogenic and mitochondrial disorders.

Stem‑Cell‑Derived Gametes (In Vitro Gametogenesis)

Induced pluripotent stem cells (iPSCs) can be coaxed into primordial germ‑cell‑like cells and further differentiated into functional oocytes or spermatozoa.

• This strategy offers a potential solution for individuals lacking viable gametes because of congenital disorders, cancer treatment, or age‑related depletion.
  
• Combining iPSCs with gene editing and organ‑on‑chip monitoring provides a roadmap for generating patient‑specific gametes while checking for genetic or epigenetic abnormalities.
  

If successfully translated to humans, in‑vitro gametogenesis could enable same‑sex couples to have genetically related children and give hope to those with irreversible gamete loss.

Ethical Horizon and Future Challenges

As these technologies advance, they raise profound ethical, social, and economic questions.

• In‑vitro gametogenesis (IVG) could redefine parentage and family structures but also stoke fears of “designer babies” if polygenic risk scores are used for trait selection, debates already sparked by firms offering such screening.
• Access and equity – The high cost of robotic systems, 3D‑printed tissues, and specialised reagents risks creating a fertility divide where only affluent patients benefit. Ensuring broad accessibility will be a central goal for the next decade [user content].
• Safety and regulation – Long‑term studies are needed to assess off‑target effects of CRISPR, the tumorigenic potential of stem‑cell therapies, and developmental outcomes of organ‑on‑chip‑derived gametes.
  

Responsible innovation will require inclusive policymaking, rigorous clinical trials, and ongoing public dialogue.

Conclusion

Bioengineering has transformed infertility from a largely manual, trial‑and‑error process into a technological platform characterised by precision, automation, and personalization. Tissue‑engineered uterine and ovarian repairs restore native organ function; microfluidic sperm selection reduces DNA damage and boosts fertilization; AI‑driven robotics elevate embryo‑selection accuracy beyond human capability; 3D bioprinting builds living ovarian and uterine scaffolds; CRISPR and MRT prevent hereditary disease transmission; and stem‑cell‑derived gametes open the door to genuine gamete regeneration.

Together, these advances are raising success rates, reducing the emotional and physical toll of failed cycles, and extending hope to those previously told they had no options. As the field moves from laboratory breakthroughs to widespread clinical use, the continued convergence of engineering, biology, and data science promises a future where building a family is more reliable, successful, and inclusive than ever before.